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Summary.-In a group of74 patients with advanced metastatic breast cancer,570/' of
those with cytoplasmic oestrogen receptor activity in their tumours (REc+) showed
a clinical response to endocrine therapy. Of 51 patients whose tumour was assayed
for both REc and cytoplasmic progesterone (RPc) activity, 9/12 patients with REc+
RPc+ tumours responded to hormone treatment, whereas only 3/30 patients with
REc-RPc- tumours had a clinical response. In a group of 19 patients in whom nuclear
oestrogen receptor (REN) was also estimated in the pellets from tumour-tissue
homogenates,5/6 with tumours positive for all 3 receptors showed a clinical response.
None of the 9 patients with triply negative tumours responded. Addition of the REN
assay appears to reinforce the greater precision of prediction when RPc as well as
REc are estimated in breast tumours.
THE USEFULNESS of the evtoplasmic
oestrogen receptor (REC) assay to predict
response to endocrine therapy of meta-
static breast carcinoma, irrespective of
whether ablative, additive or anti-
oestrogen treatment, is used, is now well
established (McGuire etal., 1975; McC'ruire,
1978). Our own data (Tables I and 11) are
representative of most. The fact that
about 400/,) of REC+ tumo-Lirs fail to
respond indicates the need for additional
markers to identify the responsive
tumours. Cytoplasmic progesterone re-
ceptor (RPc), whose svnthesis in normal
reproductive tissue is dependent on
oestrogen stimulation, and which may be
regarded as a translation product of cells
whose regulatory mechanism has re-
mained intact, seemed to us likely to
indicate those tumours wliich remained
endocrine-responsive (Horwitz et al.,
1.975). We therefore developed a method
for rotitine estimation of both specific,
oestrogen and progesterone receptor in
the same tunio-Lir cytosol (Barnes et al.,
1977).
Correlatioii of clinical i-esponse with
receptor status for both REC and RPC
indicates that patients whose tumours are
positive for both cytoplasmic receptors
are the most likely to respond to hormone
therapy. With the object of further im-
proving the prognostic value of our re-
ceptor measurements, we have now added
to the two existing cytoplasmic assays the
estimation of oestrogen receptor sites
(REN) in the residual washed pellets from
our tissue homogenates, which may serve
as an indication of an intact nuclear trans-
location mechanism, as suggested bv
Laing et al. (1,977).
We now present an interim report on
the improved prediction of hormonal
dependence of advanced breast tumours
achieved by the triple hormone-receptor
assaiT over that derived from REc assav
alone.
PATIENTS AND METHODS
Patienis assessed foi- clinical req)on,se.-All
patients included in this study -were seen at
the Christie Hospital. Thev liad recurrent oi-
metastatic breast cancer, oroccasionally local
advanced inoperable 1)reast caiieer. None, ha(i863 RECEPTOR ASSAY AND BREAST CANCER PROGNOSIS
previously been given additive hormonal
therapy or cytotoxic drugs. All except 5 were
post-menopausal. All hadprogressive disease,
measurable clinicallyand/orradiologically.
Accessible metastatic lesions were biopsied
immediately before treatment was started;
half the tissue sample taken was sent for
histological examination and the rest used
forreceptor assay. The result ofthe assay was
not known to the clinician, and the patient
was given the endocrine therapy thought
most suitable in her circumstances. Accurate
measurements were taken of all visible and
palpable lesions before therapy was started,
and where possible clinical photographs were
taken. A chestX-ray andX-rays ofthemajor
portions of the skeleton were carried out.
Each patient was reassessed at 6 months or
more from the start oftherapy. The criteria
of response were those recommended by the
UICC Working Party (1977). The minimum
follow-up time was 8 months and the maxi-
mum 4 years.
Receptor assays.-Biopsy samples from
metastatic skin deposits were taken under
local anaesthesia. The samples were freed
from surrounding fat and connective tissue,
cut to a convenient size and placed imme-
diately in vials inliquidN2. In ourexperience,
tumours stored in liquid N2 retain REc
activity for over 2 years and RPC activity for
at least I year (Barnes et al., 1979). Where
possible, 500 mg of tumour tissue was ob-
tained; the assays may be carried out success-
fully with less, but sometimes the prepared cytosol will have too low a protein concen-
tration for reliable results.
Preparation of cytosol and estimation of
specific cytosol receptor activities (REC and
RPc) were carried out using the dextran-
charcoal methodpreviouslydescribed (Barnes
et al., 1977). The synthetic progestin [3H]- R5020 (Roussel-UCLAF) was used in the
RPC assays. The criteria for determining whether a specimen had positive cytoplasmic
receptor activity were: (a) that it should
contain a minimum of 5 fmol (REc) or 15
fmol (RPc)/mg cytosol protein; (b) that the
results provided a satisfactory Scatchard
analysis with a Kdwithin the range 0.5-5.0
x 10-10m for REc and 2.0-14.0 x 10-10m for
RPc. Negative results were only accepted as
valid if the cytosol protein content was
0
-7 mg/ml.
Quality control of the cytoplasmic assay systems was exercised by preparation of a
pool of cytoplasm from accumulated liquid
N2-frozen receptor-positive tumour tissue.
This pool of cytoplasm was aliquoted into
5OOtLI lots which were stored inliquidN2. One
aliquot of the pool was estimated (single-
point assay) with each batch of tumour
cytosols assayed for REC and RPC.
"Nuclear" oestrogen receptor activity
(REN)was estimated in the pellets removed
from the tissue homogenates, after a pre-
liminary centrifugation at 800 g, by a pro-
cedure similar to that of Laing et al. (1977).
A Kdof 2-2 +0-7 (s.e.) x 10-10m for RENwas
obtained by this method which appears to
measure unoccupied sites. A tumour speci-
men was classified as "Positive" forRENonly when the results provided a satisfactory Scratchardanalysis.
RESULTS
Cytoplasmic oestrogen-receptor assay
was carried out on tumourbiopsy samples
from 74 patients with advanced breast
cancer. Thirty patients had REC+
tumours, those ofthe other 44beingREC-.
As shown in Table 1, 57% of the patients
with REc+ tumours showed a clinical
TABLE I.-REc+ Metastatic tumours: re-
sponse to hormone therapy in 30patients
Response
Com- Par- No Fail----I
Patients plete tial change ure
18 5 5 2 6
8 1 3 1 3
I I
I I
Initial
therapy
Tamoxifen
Stilboestrol
Progesterone
Prednisolone
Tamoxifen+
prednisolone 2 2
30 7 10
k
57%
3 10
9% 34%
TABLE II.-REc- metastatic tumours: re-
sponse to hormone therapy in 44patients
Response
A
Initial Com- Par- No Fail-
therapy Patients plete tial change ure
Tamoxifen 29 1 3 2 23
Stilboestrol 6 1 5
Progesterone I I
Prednisolone 3 3
Ovarian ablation 3 3
Androgens 2 2
44 2 3
11%
2 37
84%864 D. M. BARNES, L. G. SKINNER AND G. G. RIBEIRO
response (complete or partial) to additive
hormonal therapy, 34% failed to respond
and the remaining 9% showed no change.
Of the 44 patients with REC- tumours
(Table 11), 37 (84%) failed to respond and
2 showed no change.
In 51 of these patients, cytoplasmic
progesterone receptor was also measured.
Table III summarizes clinical response in
relation to receptor status for both REc
and RPC.
TABLE III.-Cytoplasmic oestrogen and
progesterone receptors and response to
endocrine therapy in 51 patients tvith
metastatic tumours
Receptor status
Clinical
REc RPC Patients response*
+ + 12 9 (75%)
+ 6 2
+ 3 2
30 3 (10%)
Complete or partial.
Since we have added estimation of
oestrogen receptor sites in the residual
washed pellets from the tumour tissue
homogenates (so-called "nuclear" oestro-
gen receptor, REN) to our routine exami-
nations of tumours, 19 patients have
become eligible for assessment. Of these
(Table IV), 5/6 with tumours positive for
TABLEIV.-REc, REN, RPc and response
to endocrine therapy in 19 patients:
metastatic tumours
TABLEV.-Incidence of REC, REN, and
RPC in 97 metastatic breast tumours
REc REN RPC Total %
+ + + 21 22
+ + 10 10
+ 4 4
+ + 0 0
Subtotal 35 36
54 56
+ 8 8
+ + 0 0
+ 0 0
Subtotal 62 64
receptor system over a random group of
tumours. Notably, a lower proportion of
metastatic tumours (22%), asagainst 30%
in aparallelstudy of 187 primary tumours
(to be reported), appear to have retained
the ability to carry out both translocation
of the receptor complex into the nucleus
and subsequent synthesis of the end-
product, progesterone receptor. Again, a
higher proportion of secondary tumours
(56%) as against 41% of the primary
tumours was without receptor activity.
DISCUSSION
Consideration of clinical response in
relation to receptor status for both REC
and RPC (Table 111) shows that, whereas
of 12 patients with both receptors present
nine showed an objective response to
hormone treatment, only 3/30 patients
without detectable receptor sites re-
sponded. The small numbers of patients
yet available for clinical assessment in the
groups in which only one or other receptor
activity is present preclude adequate
evaluation of the prognostic usefulness of
RPC at this stage. However, it seems to be
clear that patients whose tumours are
positive for both REC and RPC are the
most likely to respond to hormone
therapy.
Laing et al. (1977) have referred to the
oestrogen receptor sites in the residual
washed pellets from tumour-tissue homo-
genates as "nuclear" oestrogen receptor,
but precisely what is being measured is
uncertain. We compared estimates of RE
sites obtained from the same tissue pellet by the Laing procedure with those ob-
Receptor status
I
REC REN RPC Patients
+ + + 6
+ I
+ 3
9
* Complete or partial.
Clinical
response*
5
1
2
0
all 3 receptors have shown an objective
clinical response. None of the 9 patients
with triply receptor-negative tumours
responded.
Table V shows the incidence of both
cytoplasmic receptors and the pellet
oestrogen receptor in 97 metastatic breast
tumours, and illustrates the variable
spectrum of physiological integrity of theRECEPTOR ASSAY AND BREAST-CANCER PROGNOSIS 865
tained by the Garola & McGuire method
(1977), in which a 0-6m KCI extract of
receptor protein is pre-adsorbed on to
hydroxyapatite before incubation with
3H-oestradiol and which, by incubating at
both O' and 30'C, claims to measure both
unoccupied and total nuclear receptor
sites. Qualitatively, the results obtained
from the two methods were in complete
agreement with respect to the presence or
absence of detectable oestrogen receptor.
The crude pellet method, however, con-
sistently gavehigher estimates ofthe total
number of "nuclear" receptor sites in
REN+ tumours. In our hands, the crude
pellet procedure gave consistently good
Scatchard plots with Kd= 2-2 + 0-7 (s.e.)
x 10-10m, a Kd value close to that we
observe for REC (Barnes et al., 1977). It
may well be that in addition to measuring
nuclear oestrogen receptor sites (or at
least the ones unoccupied at 4'C) the
crude pellet procedure measures cyto-
plasmic receptor attached to reticular
endothelium and cytoplasmic organelles.
However, from the standpoint of pro-
viding as much information as possible to
the clinician from the minimal amounts of
tumour tissue available, the important
point seems to be that the crude pellet
assay measures specific receptor which
would otherwise escape detection, without
the need of additional tissuesample or the
relative degree ofsophistication which the
isolation of nuclei or even the use of
questionably complete salt extraction
would introduce into a routine clinical
assay.
Of the limited numbers ofpatients who
have become eligible for assessment to
date and in wbom triple receptor assay of
the tumour was carried out (Table IV),
the majority with tumours positive for all
3, receptors have shown an objective
clinical response, whereas no patient with
triply negative tumours responded. Infor-
mation on clinical response is still lacking
for those tumours which have an incom-
plete complement of receptor activity. It
is, however, of interest that 2/3 tumours
with RP, sites, but no measurable REc
activity (and which represent 8% of all
metastatic tumours; Table V), responded
to hormone therapy. Leavitt et al. (1977)
have reported oestrogen-independent RPc
in oestrogen target cells. It may well
prove to be that the presence of RPC is a
much more accurate predictor of hormone
responsiveness than that of REC.
Much larger numbers of patients will
require to be assessed before definite con-
clusions can be reached, but the addition
of the so-called nuclear receptor would
appear to reinforce the greaterprecision of
prediction obtained by adding RPc to
REC measurement. It remains to be seen
whether this effect will be confirmed.
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